NASDAQ: ONCO

Onconetix, Inc.

Healthcare · Biotechnology

After hours: $0.95(-5.22%) · as of 7:58 PM ET

Data caution

Per-share valuation inputs need verification

Event dated Mar 31, 2026

Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.

Market Cap

$3.60M

52w High

$209.50

52w Low

$0.67

P/E

-0.11

Volume

383.26K

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.

1Y Price: -99.34%Revenue (TTM): -61.81%FCF (TTM): -34.48%

What changed

The stock fell 99.34% over the last year. Revenue declined 61.81% over the trailing twelve months. Operating margin moved from -2,444.26% to -922.72%. Free cash flow declined 34.48% over the trailing twelve months.

What the market seems to be pricing

The market appears to be responding to weaker operating momentum rather than only rerating the stock.

What would invalidate this read

Operating margin stands at -922.72%. Revenue declined 61.81% — this read reverses if that trend stabilizes. Free cash flow fell 34.48% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.

Company profile

Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide.

CEODavid Allan White

SectorHealthcare

IndustryBiotechnology

Employees8

IPO dateFeb 18, 2022

https://www.onconetix.com

Valuation

Forward P/E—

EV/EBITDA-18.91

Enterprise value$250.82M

Stock splits

May 21, 2026↓ Reverse

Every 10 shares became 1

-90%

Mar 25, 2026↓ Reverse

Every 5 shares became 1

-80%

Jun 13, 2025↓ Reverse

Every 85 shares became 1

-99%

Sep 24, 2024↓ Reverse

Every 40 shares became 1

-97%

Profitability & growth

Revenue growth-78.89%

Gross margin79.63%▲85.70%vs FY2024

Operating margin-922.72%▲65.23%vs FY2024

ROE-89.01%▲85.42%vs FY2024

Analyst consensus

RatingBuy

Target price—

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Aug 17, 2026

Q3 FY26 · EPS est -$4,505.00 · Revenue est $21.88K

View